The United States Patent and Trademark Office (USPTO) has issued Axcentua Pharmaceuticals the USPTO patent no 7, 863, 325 B2 entitled “Crystalline Genistein Sodium Salt Dihydrate”. The patent covers Axcentua’s novel crystalline composition of genistein, AXP107-11 and its medical uses

Axcentua Pharmaceuticals AB today announced that the first patient has been enrolled in the clinical trial AXP-CT-001 (www.clinicaltrials.gov). The study is designed as a phase Ib/IIa study for the treatment of pancreatic cancer with AXP107-11 in combination with gemcitabine.

Dr. Stefan Rehnmark is appointed as new CEO of the company Axcentua Pharmaceuticals. Dr. Anders Berkenstam has decided to resign after three years as CEO for Axcentua Pharmaceuticals as the company now is moving into a more operational mode. Dr. Berkenstam will remain as a member of the board of directors and a major shareholder.